The US Department of Health and Human Services (HHS) has warned that more than 32,000 of its staff could be furloughed if ...

US drugmaker AbbVie has announced plans to launch Elahere (mirvetuximab soravtansine-gynx) in the UK at a list price equal to the USA.

US biotech Star Therapeutics, which is developing best-in-class antibodies for bleeding disorders and other diseases, today announced an oversubscribed $125 million Series D financing. This adds to ...

Shares in Enanta Pharmaceuticals, a US biotech creating small molecule drugs for viral infections and immunological diseases, ...

Privately-held French biotech focused on providing immuno-therapeutics Biomunex Pharmaceuticals today announced a capital ...

US obesity firm Metsera has presented new data that demonstrates why pharma giant Pfizer is paying up to $7.3 billion to buy the company in an acquisition announced last week.

Japanese drugmaker Eisai and US biotech major Biogen have presented new clinical data from a post-hoc sub-group analysis of the Clarity AD, open-label extension (OLE) study.

Shares of US clinical-stage biotech Dogwood Therapeutics soared a massive 43% to $7.91 yesterday, on the news it has secured ...

US health technology body ICER will review the comparative clinical effectiveness and value of four COVID-19 vaccines: Pfizer ...

Since my first job in healthcare over 25 years ago to my current role within Gilead UK&I, I have seen time and time again ...

For years, rare diseases were seen as a safe harbor for biotech and pharma: small patient populations, little competition, and robust pricing that payers accepted. That era is ending. The orphan drug ...

US eye disease specialist Kala Bio saw its shares close down almost 90% at $2.04 yesterday, after it revealed disappointing trial results for its KPI-012.